MedTrace Logo

The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome

NCT01753674 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2015-05-28

No results posted yet for this study

Summary

Our hypothesis is that TA-65, a dietary supplement will help to reduce insulin resistance and plasma glucose in individuals classified with metabolic syndrome.

Conditions

Interventions

DIETARY_SUPPLEMENT

TA-65

TA-65 will be provided to volunteers, 2 pills per day of 8 mg each

DIETARY_SUPPLEMENT

Placebo

Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each

Sponsors & Collaborators

  • University of Connecticut

    lead OTHER

Principal Investigators

  • Maria-Luz Fernandez, Ph.D. · University of Connecticut

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01753674 on ClinicalTrials.gov